Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|December 11, 2019

7 Trends in Digital Mental Health for 2020

Author(s)John Torous, MD, MBI

It has been a busy year for digital mental health. While no one knows what 2020 will bring, some themes are sure to continue to shape the field.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

andranik123/Adobe Stock

Morning Rounds: August 24-31

ByJessica Walters

August 31st 2026

Quantifying the Specific Contribution of Wearable and Biomarker Data to Patient Outcomes

ByScott Fears, MD

August 30th 2026

Tying Wearable Biomarkers to Value-Based Care in Psychiatry

ByScott Fears, MD

August 29th 2026

teen social media

An Update on the Harms of Social Media on Teen Mental Health: Meta Settles for $18 Billion

August 28th 2026

Bringing Wearable Device Data Into Psychiatric Care

ByScott Fears, MD

August 27th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

The Postmodern Worldview and Contemporary Psychiatry

Choosing Sexual Function-Sparing Medications

Anita Clayton, MD, on Diagnosing and Discussing Sexual Dysfunction